The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange

Transfusion

Volumn 50, Issue 8, 2010, Pages 1654-1664

  Bentley, Melissa J ^a,b   Lehman, Chris M ^a,b   Blaylock, Robert C ^a,b   Wilson, Andrew R ^a,b   Rodgers, George M ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Ogden Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROTEIN DEFICIENCY; RECEIVER OPERATING CHARACTERISTIC; RETICULOCYTE; RETICULOCYTE COUNT; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE DEFICIENCY; ADOLESCENT; AGED; BLOOD; CHILD; DEFICIENCY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETROSPECTIVE STUDY; VERY ELDERLY;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETROSPECTIVE STUDIES;

EID: 77955160643     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02653.x     Document Type: Article

References (23)

1. Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007 21 : 609 32.
2. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924 24 : 21 4.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002 347 : 589 600.
4. Crowther MA, George JN. Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med 2008 75 : 369 75.
5. Shepard KV, Bukowski RM. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol 1987 24 : 178 93.
6. Lara PN, Coe TL, Zhou H, Fernando L, Hollar PV, Wun T. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 1999 107 : 573 9.
7. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 307 : 1432 5.
8. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 87 : 4235 44.
9. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 87 : 4223 34.
10. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008 112 : 11 7.
11. Veyradier A, Obert B, Houlllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombomicroangiopathies: a study of 111 cases. Blood 2001 6 : 1765 72.
12. Zbigniew MS, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories - introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apheresis 2007 22 : 96 105.
13. Shelat SG, Ai J, Zheng XL. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 2005 31 : 659 72.
14. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009 53 : 259 72.
15. Groot E, Julstein JJ, Rison CN, De Groot PG, Fijnheer R. FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Thromb Haemost 2005 4 : 698 9.
16. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000 83 : 416 20.
17. Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007 5 : 866 7.
18. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 : 1578 84. (Pubitemid 28536132)
19. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102 : 60 8.
20. Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Minerva Med 2007 6 : 731 47.
21. Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004 44 : 146 50.
22. Tsai HM. Thrombotic thrombocytopenic-purpura, hemolytic uremic syndrome, and related disorders. In : Greer JP, Foerster J, Rodgers GM, editors. Wintrobe's clinical hematology. 12th ed. Philadelphia (PA) : Lippincott Williams & Williams 2008. p. 1314 21.
23. Cataland SR, Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 2009 83 : 559 64.